Note 30.16 Segment information a) Description of segments and principal activities The Group has determined the following reporting segments, based on the information reviewed by the Chief Operating Decision Maker: Name of segment Product groups Life Science Chemicals Active pharmaceutical ingredients and its intermediates, Crop protection chemicals Performance and Other Chemicals Adhesion promoters, Bulk chemicals, Epoxy resins and hardeners, Intermediates, Textile dyes Others Agribiotech, Food products, Services and others b) Operating segment (` cr) Particulars Life Science Chemicals Performance and Other Chemicals Others Total 2024-25 2023-24 2024-25 2023-24 2024-25 2023-24 2024-25 2023-24 i) Segment revenue Gross sales 1,691.67 1,426.70 4,058.24 3,453.10 73.92 63.26 5,823.83 4,943.06 Less: Inter-segment revenue 0.25 0.29 240.23 217.09 - - 240.48 217.38 Net revenue from operations 1,691.42 1,426.41 3,818.01 3,236.01 73.92 63.26 5,583.35 4,725.68 ii) Segment results Profit before finance cost and tax 346.76 203.05 344.85 239.79 12.30 5.69 703.91 448.53 Less: Finance costs 23.98 11.08 Less: Other unallocable expenditure (net of unallocable income) (1.26) (3.47) Add: Share of net profit of joint venture company 11.30 9.70 Profit before tax 692.49 450.62 iii) Other information Segment assets 1,323.82 1,234.87 3,646.17 3,532.60 222.60 199.73 5,192.59 4,967.20 Unallocated common assets 1,808.40 1,509.08 Total assets 7,000.99 6,476.28 Segment liabilities 285.31 253.59 731.42 783.99 25.26 32.95 1,041.99 1,070.53 Unallocated common liabilities 296.63 242.36 Total liabilities 1,338.62 1,312.89 Additions to assets and intangible assets 64.21 138.39 150.41 336.57 0.34 0.30 214.96 475.26 Unallocated additions to assets and intangible assets 1.20 22.69 Total capital expenditure* 216.16 497.95 Depreciation 65.03 59.51 240.80 173.81 5.31 5.14 311.14 238.46 Unallocated depreciation 5.69 4.42 Total depreciation 316.83 242.88 298 298 Integrated Annual Report 2024-25
RkJQdWJsaXNoZXIy MjA2MDI2